In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 31 to 40 of 303

TitleTypeExpected publication date
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Technology appraisal guidance
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Technology appraisal guidanceTBC
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462Technology appraisal guidance
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]Technology appraisal guidance
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]Technology appraisal guidanceTBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All